Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $2.4B | $2.3B | $2.2B | $1.8B | $1.6B | $1.4B | $988M | $968M | $854M | $452M | $191M | $37M | $25M | $31M | $47M | $290M | $185M | $152M | $118M | $113M | $99M |
| Bruttoergebnis | $2.4B | $2.2B | $2.1B | $1.8B | $1.6B | $1.4B | $951M | $935M | $827M | $437M | $185M | $33M | $23M | $30M | $47M | $290M | $185M | $152M | $118M | $113M | $98M |
| Bruttomarge % | 96.4% | 96.4% | 96.5% | 96.0% | 96.4% | 96.3% | 96.3% | 96.6% | 96.9% | 96.7% | 96.6% | 89.5% | 91.9% | 96.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.8% | 99.2% |
| Betriebsergebnis (EBIT) | $971M | $872M | $605M | $171M | $201M | $287M | $110M | $369M | $439M | $166M | ($28M) | ($121M) | ($224M) | ($201M) | ($122M) | $90M | ($91M) | ($122M) | ($179M) | ($157M) | ($127M) |
| Operative Marge % | 39.8% | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% | 11.1% | 38.2% | 51.4% | 36.7% | -14.7% | -326.7% | -893.9% | -640.5% | -258.0% | 30.9% | -49.4% | -80.3% | -152.1% | -138.4% | -128.5% |
| Jahresüberschuss | $861M | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | ($70M) | ($170M) | ($269M) | ($245M) | ($148M) | $76M | ($92M) | ($135M) | ($163M) | ($86M) | ($101M) |
| Nettomarge % | 35.3% | 33.7% | 24.0% | 11.3% | 11.3% | 16.1% | 11.3% | 33.2% | 80.8% | 34.1% | -36.7% | -456.6% | -1069.4% | -781.0% | -311.2% | 26.1% | -49.9% | -89.1% | -138.2% | -76.1% | -102.9% |
| EBITDA | — | $922M | $719M | $283M | $222M | $300M | $119M | $378M | $452M | $167M | ($22M) | ($120M) | ($213M) | ($196M) | ($115M) | $100M | ($73M) | ($116M) | ($156M) | ($157M) | ($110M) |
| Ergebnis je Aktie (EPS) | $3.17 | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 | $0.35 | $1.02 | $2.21 | $0.49 | $-0.28 | $-0.81 | $-1.38 | $-1.33 | $-0.92 | $0.58 | $-0.85 | $-1.26 | $-1.54 | $-0.87 | $-1.17 |
| Ausstehende Aktien (Mio.) | — | 282M | 296M | 321M | 325M | 322M | 318M | 315M | 313M | 312M | 251M | 209M | 194M | 184M | 160M | 130M | 109M | 107M | 105M | 99M | 87M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für EXEL. /companies/us/EXEL
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms